{"name":"Boston Scientific","slug":"boston-scientific","ticker":"BSX","exchange":"NYSE","domain":"bostonscientific.com","description":"Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.","hq":"Marlborough, MA","founded":1979,"employees":"59000","ceo":"Michael F. Mahoney","sector":"Medical Devices","stockPrice":53.13,"stockChange":0.07,"stockChangePercent":0.13,"marketCap":"$79.0B","metrics":{"revenue":20614000640,"revenueGrowth":11.6,"grossMargin":68.9,"rdSpend":0,"netIncome":2892000000,"cash":1452999936,"dividendYield":0,"peRatio":22.2,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"TAXUS patent cliff ($1.2B at risk)","drug":"TAXUS","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"PROMUS patent cliff ($800M at risk)","drug":"PROMUS","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"polidocanol injectable foam, 0.5%","genericName":"polidocanol injectable foam, 0.5%","slug":"polidocanol-injectable-foam-0-5","indication":"Treatment of varicose veins and telangiectasias","status":"phase_3"},{"name":"Anti-coagulation therapy","genericName":"Anti-coagulation therapy","slug":"anti-coagulation-therapy","indication":"Other","status":"phase_3"},{"name":"P2Y12 antagonist","genericName":"P2Y12 antagonist","slug":"p2y12-antagonist","indication":"Other","status":"marketed"},{"name":"Thienopyridine","genericName":"Thienopyridine","slug":"thienopyridine","indication":"Other","status":"phase_3"},{"name":"Varithena®","genericName":"Varithena®","slug":"varithena","indication":"Varicose veins of the great saphenous vein, accessory saphenous vein, and visible varicosities","status":"marketed"},{"name":"polidocanol injectable foam, 1.0%","genericName":"polidocanol injectable foam, 1.0%","slug":"polidocanol-injectable-foam-1-0","indication":"Treatment of varicose veins and spider veins","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Anti-platelet therapy","genericName":"Anti-platelet therapy","slug":"anti-platelet-therapy","indication":"Acute coronary syndrome","status":"phase_3"},{"name":"Anticoagulation with heparin","genericName":"Anticoagulation with heparin","slug":"anticoagulation-with-heparin","indication":"Acute thromboembolism prevention and treatment","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BGC20-0582","genericName":"BGC20-0582","slug":"bgc20-0582","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"Anti-platelet therapy","genericName":"Anti-platelet therapy","slug":"anti-platelet-therapy","phase":"phase_3","mechanism":"Anti-platelet therapy inhibits platelet aggregation to prevent blood clots and reduce thrombotic events.","indications":["Acute coronary syndrome","Stroke prevention","Peripheral arterial disease","Post-percutaneous coronary intervention"],"catalyst":""},{"name":"BGC20-0582","genericName":"BGC20-0582","slug":"bgc20-0582","phase":"phase_2","mechanism":"BGC20-0582 is a drug that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"polidocanol injectable foam, 0.5%","genericName":"polidocanol injectable foam, 0.5%","slug":"polidocanol-injectable-foam-0-5","phase":"phase_3","mechanism":"Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein.","indications":["Treatment of varicose veins and telangiectasias"],"catalyst":""},{"name":"Anti-coagulation therapy","genericName":"Anti-coagulation therapy","slug":"anti-coagulation-therapy","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anticoagulation with heparin","genericName":"Anticoagulation with heparin","slug":"anticoagulation-with-heparin","phase":"marketed","mechanism":"Heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","indications":["Acute thromboembolism prevention and treatment","Atrial fibrillation with stroke risk","Deep vein thrombosis prophylaxis and treatment","Pulmonary embolism prophylaxis and treatment","Acute coronary syndrome"],"catalyst":""},{"name":"P2Y12 antagonist","genericName":"P2Y12 antagonist","slug":"p2y12-antagonist","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Thienopyridine","genericName":"Thienopyridine","slug":"thienopyridine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Varithena®","genericName":"Varithena®","slug":"varithena","phase":"marketed","mechanism":"Varithena is a microfoam formulation of polidocanol that destroys varicose veins by causing endothelial damage and subsequent vein closure.","indications":["Varicose veins of the great saphenous vein, accessory saphenous vein, and visible varicosities"],"catalyst":""},{"name":"polidocanol injectable foam, 1.0%","genericName":"polidocanol injectable foam, 1.0%","slug":"polidocanol-injectable-foam-1-0","phase":"phase_3","mechanism":"Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.","indications":["Treatment of varicose veins and spider veins"],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Boston Scientific Reports Fourth-Quarter and Full-Year 2023 Results","summary":"Boston Scientific reported fourth-quarter and full-year 2023 results, with revenue of $3.4 billion and adjusted earnings per share of $0.38.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Boston Scientific to Acquire Lumenis for $1.7 Billion","summary":"Boston Scientific announced that it has entered into a definitive agreement to acquire Lumenis, a leading provider of minimally invasive laser and light-based medical technologies.","drugName":"","sentiment":"positive"},{"date":"2023-09-22","type":"regulatory","headline":"FDA Approves Boston Scientific's WATCHMAN FLX Left Atrial Appendage Closure Device","summary":"The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's WATCHMAN FLX left atrial appendage closure device for the prevention of stroke in patients with atrial fibrillation.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQUlBtVmFmMXRiSFZRd0NVekRFZjBDOWlEcVVSZFBFc2k4NXh2bHdDXzdXb3JlWDlzemhIcVIxdDlPSUc0YWo2WUVpSklQancyNG00S3hwQ21nYWtPV0FwNFB4VnpJVnRlU1FDX05DUmFJV1Z2eC1qeklHcDY1YkNmVExDNjdtNldWdDdQcGhHZVc0UldhMUU2R0VoZGtGSk1v?oc=5","date":"2026-03-20","type":"pipeline","source":"Yahoo Finance","summary":"Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore” - Yahoo Finance","headline":"Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSzdlVkpFeGptTlVsTGJ0TGRUeDdKVC03WjE2TmFZc3dyZGhtb1lkRFpEYTBpbXJUREV4YW4zV2RqUE9EYUdvU3lVYVpIa1p3V2VHcW51eXV6Mnk0dW9RWi1ORmhKVlU1WkRzYW5XUDA0eGpHWG1zLTlrQjZTUk5wTzdDQWdlRHoyU1FyVlJ3VW8xNjVZ?oc=5","date":"2026-02-24","type":"deal","source":"The Business Journals","summary":"Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree - The Business Journals","headline":"Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZlZEaTk0dWlaWUxmbTFhMzF6TVhTZFdCWUtQVkhpWVMydjVjQmJ6Q1ZxTlhWeklPMzF0ZWlzVzNUaFFyN0NReFJxNzQxcDR5cTlWMUFFeUdFdEI1NXQ0Mm9vV2tHMDh5czd3OGozalgwZkVfd2g4WmxQalZEZkZlbDVWMkxOWGo4?oc=5","date":"2026-02-23","type":"pipeline","source":"MassDevice","summary":"Boston Scientific adds Starbucks CFO, Takeda CEO to board of directors - MassDevice","headline":"Boston Scientific adds Starbucks CFO, Takeda CEO to board of directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOeVBPZ2l3ejNORGNRTFVUZ0FUSXhlZGJMZk9zVmZYZW9CU0cxYmdHNl9HVlpTbVlJN2ZlUWV4XzdIeGgtbUJLRkNxU01iUHBMRjlJRUxqVnM4SHhOc0U1T3V3dGxhekliaUVFbzl4TUZQQkZodVhibDlvdWtydG9VT3ZWaDYwbkFwRElYdzRud1BnTW1WaG9OZUdJXzZfcjU2ajVLRFNPOGRxR1NILVE?oc=5","date":"2026-02-23","type":"deal","source":"TipRanks","summary":"Boston Scientific Expands Board and Boosts Share Buybacks - TipRanks","headline":"Boston Scientific Expands Board and Boosts Share Buybacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPTnFkRkRCN0M0ZV9hZkJiNHE0U3NaR3ZMSTdRY0tnWUd4UGJEaXNwcWVsMy15TlhwbU1wTklMUjd1YXdGSmdKRXQ2cjBPRkZDMG5Ud21NdHN6bThud2FCRUxiSVlEWU1qaVVfR0VhNW1rNmJqM1JoQVoxRlotX09ROW4zWWZfdWd5RFN2TmFHR0JBdVhGXzZfRWx1QVlyQ0M0Wm5ucFViS0JkcVl5TjJVZnJUb0kwb3g4bmNtUUdfYW9kZDUtbFgyVGc1U2NGQQ?oc=5","date":"2026-02-04","type":"pipeline","source":"reuters.com","summary":"Boston Scientific shares fall as key segment's performance spooks investors - reuters.com","headline":"Boston Scientific shares fall as key segment's performance spooks investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNaXllVGloSThjUm4xYk5QalY3LUNpYjlTSFpfREFyelI3T0R0LXRfb1pyOE12ZUVuZHFZdTI2RHo4eWt5NENqRGl1QU1NLThoZUFJNGl6VDVTZllaVmhOZmFla2c3SU1DUS1oOHE3NEtaak9RMW1jVmo4S2hzQTZLam5tUldiMHdEVUpVYlFfdWc5azZZZGMzbWljT3NzMnp6aVZFWWFCZy1TS0tDZUVmSGFqYlViWEcxSTU5R0dseDZZVjIyWU1xSF9xOEtmbktmVzZWRzRuVGJaVmxrN1JkZnBUcXZkSnFDN0JQdFNXVEhuLUFkd3loZk54cW4xSE9pdmpTTlRhTUpIR3VsNDhvQU9B?oc=5","date":"2026-01-23","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNVVlQMElFcnlldlQ4X3R3Mko5Sy16V3ZJanZUcVpoZzgtLTczbFhpT1B4Z251bkJtM1pvMVY2N0I0bXlObHNDRjJOejQyM3FhQzZ1TVhEby1rSENPSzZCQ0JMRUhWN2MzS2xULXZYUlIxU1BqOXNIZDQ5UkZFbk8tUXkwOUN1V0xRaHMtcEhXMTVXN0lxVnhhRXhFSG4wYnZpZURZQWwzQWhOWU1qbUoxazN2VXpmY2xOSjRjWlF2dEE3X25w?oc=5","date":"2026-01-15","type":"deal","source":"reuters.com","summary":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal - reuters.com","headline":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQemI0NnB4YzZNMXNpeEc0UTN6eXF1blJneFB0OHBBZnhBbFJrU2tQUENBbGpNRzJKZzZSd0FjRXNMUXpiWUlEZ08yOFpocmlBTGxaMFVfTEo0dlBBd2NhdkFFTDhuNG16RUg3c3NtMHF6WTNROTEyV0xwWmhZTTZjRjlDeFhPRnJneDhuMG1jZUotS1F3X21WZ2ZDVnRrZXV5SF9NSEJqVlNMQmNsdjN5ZXlOdHpuQ2ZC?oc=5","date":"2026-01-15","type":"deal","source":"PR Newswire","summary":"Boston Scientific announces agreement to acquire Penumbra, Inc. - PR Newswire","headline":"Boston Scientific announces agreement to acquire Penumbra, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOWVQ5ZUFMVE03THplXy1yZmVWZVhjZWJHVklFRndMa3dpVXJCNUdCajVfdHRSUHR4NGFzNENzaEptcWdOZGVvR2hZZ1FlUkNuTHJFcEYzbFRUWndfVk5rT3lpOHFtc2RUOVA4cE1aTXVIU1d1NHcwQkU4R0stb3hkeFlZUFl3V1E?oc=5","date":"2025-12-26","type":"pipeline","source":"Yahoo Finance","summary":"A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook - Yahoo Finance","headline":"A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNT0Y4d3RLM1ZGQ1YycWFYMEJOS2Ztc3pWam1JY003MXd3S1J1WkNEajdFS2xuVktMdV9xOF9kWjV2RDVXc3UxMnRDTFphaUk1eE52Vl82RmJfcDhjWnZZLXNnTjUzWVlBaTlPTEt2b1JILWZwUTNjbkxSWTNpdGZaYzV1YWdta01CbDBKSjNSclBRV2Z5X1hxVE5RYjdINXU3QjJiazRDeDREdXIwMS1iRTJydkRjNGdvUmhLcTJJWkRwc0dMVUJlcEJ3YUpqdUVoeGc0N1lkYmpLUnRyZVE?oc=5","date":"2025-07-23","type":"earnings","source":"reuters.com","summary":"Boston Scientific lifts annual profit forecast, sees smaller tariff impact - reuters.com","headline":"Boston Scientific lifts annual profit forecast, sees smaller tariff impact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQRVhDU1VWRGdxb0FoRzFZeEpidWxPRnhWLVJ1dTlQSE9JLXZtX3k3d1RmeE8wVTRmdXBnNGRob3RqY1hIaV9HWnM4eWtsdWJJc29pX1FLZGJOM3RHRWdQZHpNNS1qVS1iZWhrWTZGMmJHMG5qZF9OSnQtaW80R3JBbXNHMzVudGIzYm56R2JVRUctOUY5SC00?oc=5","date":"2025-07-17","type":"earnings","source":"Barron's","summary":"Boston Scientific Stock Is on Pause. Its Earnings Could Get It Moving Higher Again. - Barron's","headline":"Boston Scientific Stock Is on Pause. Its Earnings Could Get It Moving Higher Again. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxORGNFcDdOZ2FxcGJMRzZYRTFmbmhDSjloVm5Ebkw3amROdjZWSTU0TWFWQXpreERyQkNrY0lPaDRobkNieWYtSk8yRzU3Y1JrZHZCdGR4Z3NnUnZ3MTlzRnVnZm84a2p2XzZ2Rk44c1NKMVRxWjRWODBCc3VBV2VwODZZWjI5T18tbnBFRw?oc=5","date":"2025-05-18","type":"pipeline","source":"The Business Journals","summary":"Market shift: Boston Scientific emerges as Massachusetts' most valuable public company - The Business Journals","headline":"Market shift: Boston Scientific emerges as Massachusetts' most valuable public company","sentiment":"neutral"}],"patents":[{"drugName":"TAXUS","drugSlug":"paclitaxel-eluting-stent","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"PROMUS","drugSlug":"everolimus-eluting-stent","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":800000000}],"drugCount":9,"phaseCounts":{"phase_3":5,"phase_2":1,"marketed":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Medtronic","Abbott Laboratories","Becton Dickinson"],"therapeuticFocus":["Cardiovascular","Neuromodulation"],"financials":{"source":"sec_edgar+yahoo","revenue":9076000000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":9076000000,"period":"2016-12-31"},{"value":8068000000,"period":"2015-12-31"},{"value":8068000000,"period":"2015-12-31"},{"value":7462000000,"period":"2014-12-31"},{"value":7462000000,"period":"2014-12-31"}],"grossProfit":13853000000,"grossProfitHistory":[{"period":"2025-12-31","value":13853000000},{"period":"2024-12-31","value":11490000000},{"period":"2023-12-31","value":9895000000},{"period":"2022-12-31","value":8727000000}],"rdSpend":2052000000,"rdSpendHistory":[{"period":"2025-12-31","value":2052000000},{"period":"2024-12-31","value":1615000000},{"period":"2023-12-31","value":1414000000},{"period":"2022-12-31","value":1323000000}],"sgaSpend":6887000000,"operatingIncome":3971000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":3971000000},{"period":"2024-12-31","value":3002000000},{"period":"2023-12-31","value":2417000000},{"period":"2022-12-31","value":2034000000}],"netIncome":2892000000,"netIncomeHistory":[{"period":"2025-12-31","value":2898000000},{"period":"2024-12-31","value":1854000000},{"period":"2023-12-31","value":1593000000},{"period":"2022-12-31","value":698000000}],"eps":1.94,"epsHistory":[{"period":"2025-12-31","value":1.94},{"period":"2024-12-31","value":1.25},{"period":"2023-12-31","value":1.07},{"period":"2022-12-31","value":0.45}],"cash":1965000000,"cashHistory":[{"period":"2025-12-31","value":1965000000},{"period":"2024-12-31","value":414000000},{"period":"2023-12-31","value":865000000},{"period":"2022-12-31","value":928000000}],"totalAssets":43673000000,"totalLiabilities":19201000000,"totalDebt":11436000000,"equity":24232000000,"operatingCashflow":4534000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":4534000000},{"period":"2024-12-31","value":3435000000},{"period":"2023-12-31","value":2503000000},{"period":"2022-12-31","value":1526000000}],"capex":-1130000000,"capexHistory":[{"period":"2025-12-31","value":-1130000000},{"period":"2024-12-31","value":-1070000000},{"period":"2023-12-31","value":-800000000},{"period":"2022-12-31","value":-612000000}],"freeCashflow":3404000000,"dividendsPaid":0,"buybacks":0,"employees":59000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1781000000,"ebit":1252000000,"ebitda":1603000000,"period":"2026-03-31","revenue":5203000000,"epsBasic":0.9,"netIncome":1341000000,"rdExpense":516000000,"epsDiluted":0.9,"grossProfit":3613000000,"operatingIncome":1072000000},{"sga":1834000000,"ebit":790000000,"ebitda":1155000000,"period":"2025-12-31","revenue":5286000000,"epsBasic":0.45,"netIncome":672000000,"rdExpense":569000000,"epsDiluted":0.45,"grossProfit":3678000000,"operatingIncome":1041000000},{"sga":1741000000,"ebit":1026000000,"ebitda":1368000000,"period":"2025-09-30","revenue":5065000000,"epsBasic":0.51,"netIncome":755000000,"rdExpense":514000000,"epsDiluted":0.51,"grossProfit":3542000000,"operatingIncome":1050000000},{"sga":1716000000,"ebit":1031000000,"ebitda":1367000000,"period":"2025-06-30","revenue":5061000000,"epsBasic":0.54,"netIncome":797000000,"rdExpense":526000000,"epsDiluted":0.53,"grossProfit":3424000000,"operatingIncome":943000000},{"sga":1597000000,"ebit":887000000,"ebitda":1212000000,"period":"2025-03-31","revenue":4663000000,"epsBasic":0.46,"netIncome":674000000,"rdExpense":443000000,"epsDiluted":0.45,"grossProfit":3210000000,"operatingIncome":937000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":53.13,"previousClose":53.06,"fiftyTwoWeekHigh":109.5,"fiftyTwoWeekLow":52.75,"fiftyTwoWeekRange":"52.75 - 109.5","fiftyDayAverage":63.73,"twoHundredDayAverage":87.99,"beta":0.62,"enterpriseValue":88682004480,"forwardPE":14.1,"priceToBook":3.05,"priceToSales":3.83,"enterpriseToRevenue":4.3,"enterpriseToEbitda":16.12,"pegRatio":0.65,"ebitda":5500000256,"ebitdaMargin":26.7,"freeCashflow":2807124992,"operatingCashflow":4341000192,"totalDebt":11029000192,"debtToEquity":42.2,"currentRatio":1.9,"returnOnAssets":6.1,"returnOnEquity":14.7,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":32,"targetMeanPrice":85.19,"targetHighPrice":110,"targetLowPrice":60,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.2,"institutionHeldPercent":94.2,"sharesOutstanding":1486355179,"floatShares":1482059613,"sharesShort":28642737,"shortRatio":1.47,"shortPercentOfFloat":1.9,"epsTrailing":2.39,"epsForward":3.76,"revenuePerShare":13.91,"bookValue":17.4,"officers":[{"age":60,"name":"Mr. Michael F. Mahoney","title":"Chairman, President & CEO"},{"age":51,"name":"Mr. Jonathan R. Monson","title":"Executive VP & CFO"},{"age":55,"name":"Mr. Vance R. Brown J.D.","title":"EVP, General Counsel & Corporate Secretary"},{"age":61,"name":"Mr. Joseph M. Fitzgerald","title":"Executive VP & Group President of Cardiovascular"},{"age":54,"name":"Mr. Arthur Crosswell  Butcher","title":"Executive VP and Group President of MedSurg & Asia Pacific"},{"age":57,"name":"Mr. Paudie  O'Connor","title":"Executive Vice President of Global Operations"},{"age":47,"name":"Ms. Emily M. Woodworth","title":"Senior VP, Global Controller & Chief Accounting Officer"},{"age":null,"name":"Mr. Adam  Smith","title":"General Manager of Global Sales & Marketing"}],"industry":"Medical Devices","irWebsite":"http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-irhome","website":"https://www.bostonscientific.com","phone":"508 683 4000"}}